Advancements in the development of subunit influenza vaccines

Microbes and Infection

Volumn 17, Issue 2, 2015, Pages 123-134

  Zhang, Naru ^a   Zheng, Bo Jian ^b   Lu, Lu ^c   Zhou, Yusen ^d   Jiang, Shibo ^a,c   Du, Lanying ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c FUDAN UNIVERSITY   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Hemagglutinin; Influenza A virus; Matrix protein; Nucleoprotein; Subunit vaccines

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; MATRIX PROTEIN; NUCLEOPROTEIN; SUBUNIT VACCINE;

ARTICLE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EXTRACELLULAR MATRIX; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A; LIFE CYCLE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; ANIMAL; GENETICS; IMMUNOLOGY; INFLUENZA A VIRUS; PATHOGENICITY; PHYSIOLOGY;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

ANIMALS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; VACCINES, SUBUNIT;

EID: 84921496495     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.12.006     Document Type: Article

References (121)

1. Cox N.J., Neumann G., Donis R.O., Kawaoka Y. Orthomyxoviruses: influenza. Topley and Wilson's microbiology and microbial infections 2010, 10.1002/9780470688618.taw0238.
2. Le T.H., Nguyen N.T. Evolutionary dynamics of highly pathogenic avian influenza A/H5N1 HA clades and vaccine implementation in Vietnam. Clin Exp Vaccine Res 2014, 3:117-127.
3. Webby R.J., Webster R.G. Are we ready for pandemic influenza?. Science 2003, 302:1519-1522.
4. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W., et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013, 368:1888-1897.
5. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258:1-20.
6. Samji T. Influenza A: understanding the viral life cycle. Yale J Bio Med 2009, 82:153-159.
7. Nayak D.P., Hui E., Barman S. Assembly and budding of influenza virus. Virus Res 2004, 106:147-165.
8. Gerhard W., Mozdzanowska K., Zharikova D. Prospects for universal influenza virus vaccine. Emerg Infect Dis 2006, 12:569-574.
9. O'Neill R.E., Talon J., Palese P. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. EMBO J 1998, 17:288-296.
10. Noah D.L., Krug R.M. Influenza virus virulence and its molecular determinants. Adv Virus Res 2005, 65:121-145.
11. Lee M.T.M., Klumpp K., Digard P., Tiley L. Activation of influenza virus RNA polymerase by the 5' and 3' terminal duplex of genomic RNA. Nucleic Acids Res 2003, 31:1624-1632.
12. Nguyen-Van-Tam J.S., Hampson A.W. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003, 21:1762-1768.
13. Taubenberger J.K., Morens D.M. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 2006, 12:15-22.
14. Reid A.H., Fanning T.G., Hultin J.V., Taubenberger J.K. Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene. Proc Natl Acad Sci U S A 1999, 96:1651-1656.
15. Reid A.H., Fanning T.G., Janczewski T.A., Taubenberger J.K. Characterization of the 1918 "Spanish" influenza virus neuraminidase gene. Proc Natl Acad Sci U S A 2000, 97:6785-6790.
16. Reid A., Fanning T., Slemons R., Janczewski T., Dean J., Taubenberger J. Relationship of pre-1918 avian influenza HA and NP sequences to subsequent avian influenza strains. Avian Dis 2003, 47:921-925.
17. Scholtissek C., Rohde W., Von Hoyningen V., Rott R. On the origin of thehuman influenza virus subtypes H2N2 and H3N2. Virology 1978, 87:13-20.
18. Kawaoka Y., Krauss S., Webster R.G. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989, 63:4603-4608.
19. Taubenberger J.K., Morens D.M. Influenza: the once and future pandemic. Public Health Rep 2010, 125:16-26.
20. Kilbourne E.D. Perspectives on pandemics: a research agenda. J Infec Dis 1997, 176:S29-S31.
21. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
22. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
23. Dunham E.J., Dugan V.G., Kaser E.K., Perkins S.E., Brown I.H., Holmes E.C., et al. Different evolutionary trajectories of European avian-like and classical swine H1N1 influenza A viruses. J Virol 2009, 83:5485-5494.
24. Morens D.M., Taubenberger J.K., Fauci A.S. The persistent legacy of the 1918 influenza virus. N Engl J Med 2009, 361:225-229.
25. Zhou N.N., Senne D.A., Landgraf J.S., Swenson S.L., Erickson G., Rossow K., et al. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. J Virol 1999, 73:8851-8856.
26. Olsen C.W. The emergence of novel swine influenza viruses in North America. Virus Res 2002, 85:199-210.
27. Pensaert M., Ottis K., Vandeputte J., Kaplan M.M., Bachmann P.A. Evidence for the natural transmission of influenza A virus from wild ducts to swine and its potential importance for man. Bull World Health Organ 1981, 59:75-78.
28. Swayne D., Suarez D. Highly pathogenic avian influenza. Revue Sci Tech (International Office of Epizootics) 2000, 19:463-482.
29. Xu X., Subbarao K., Cox N.J., Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 1999, 261:15-19.
30. Swayne D.E., Beck J.R., Perdue M.L., Beard C.W. Efficacy of vaccines in chickens against highly pathogenic Hong Kong H5N1 avian influenza. Avian Dis 2001, 355-365.
31. Meijer A., Jonges M., Abbink F., Ang W., van Beek J., Beersma M., et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antivir Res 2011, 92:81-89.
32. Shin S.Y., Kang C., Gwack J., Kim J.H., Kim H.S., Kang Y.A., et al. Drug-resistant pandemic (H1N1) 2009, South Korea. Emerg Infect Dis 2011, 17:702-704.
33. Hurt A.C., Holien J.K., Parker M.W., Barr I.G. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69:2523-2531.
34. Lavrov S.V., Podchernyayeva R.Y., Blinova V.K., Sokolov M.I. Isolation and properties of amantadine-resistant variants of influenza A virus. Acta Virol 1972, 16:507.
35. Pabbaraju K., Wong S., Kits D.K., Fox J.D. Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008). Can J Infect Dis Med Microbiol 2010, 21:e87-91.
36. Horimoto T., Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009, 333:165-176.
37. Ilyushina N.A., Haynes B.C., Hoen A.G., Khalenkov A.M., Housman M.L., Brown E.P., et al. Live attenuated and inactivated influenza vaccines in children. J Infect Dis 2014, pii: jiu458.
38. Ambrose C.S., Wu X., Caspard H., Belshe R.B. Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. Vaccine 2014, 32:5546-5548.
39. Peeters B., Tonnis W.F., Murugappan S., Rottier P., Koch G., Frijlink H.W., et al. Pulmonary immunization of chickens using non-adjuvanted spray-freeze dried whole inactivated virus vaccine completely protects against highly pathogenic H5N1 avian influenza virus. Vaccine 2014, pii: S0264-410X(14)01316-4.
40. Richt J.A., García-Sastre A. Attenuated influenza virus vaccines withmodified NS1 proteins. Curr Top Microbiol Immunol 2009, 333:177-195.
41. Overton E.T., Goepfert P.A., Cunningham P., Carter W.A., Horvath J., Young D., et al. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. Vaccine 2014, 32:5490-5495.
42. Pena L., Sutton T., Chockalingam A., Kumar S., Angel M., Shao H., et al. Influenza viruses with rearranged genomes as live-attenuated vaccines. J Virol 2013, 87:5118-5127.
43. Petricciani J.C. Regulatory philosophy and acceptability of cells for the production of biologicals. Dev Biol Stand 1991, 75:9-15.
44. Kistner O., Barrett P., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16:960-968.
45. Chen J., Liu Q., Chen Q., Xiong C., Yao Y., Wang H., et al. Comparative analysis of antibody induction and protection against influenza virus infection by DNA immunization with HA, HAe, and HA1 in mice. Arch Virol 2014, 159:689-700.
46. Xu K., Ling Z.Y., Sun L., Xu Y., Bian C., He Y., et al. Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 2011, 24:45-56.
47. Kodihalli S., Haynes J.R., Robinson H.L., Webster R.G. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol 1997, 71:3391-3396.
48. Kodihalli S., Goto H., Kobasa D.L., Krauss S., Kawaoka Y., Webster R.G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999, 73:2094-2098.
49. Park K.S., Seo Y.B., Lee J.Y., Im S.J., Seo S.H., Song M.S., et al. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 2011, 29:5481-5487.
50. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13:426-435.
51. Bragstad K., Vinner L., Hansen M.S., Nielsen J., Fomsgaard A. A polyvalent influenza A DNA vaccine induces heterologous immunity and protects pigs against pandemic A (H1N1) pdm09 virus infection. Vaccine 2013, 31:2281-2288.
52. Shamlou P.A. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol Appl Biochem 2003, 37:207-218.
53. Prather K.J., Sagar S., Murphy J., Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Micro Technol 2003, 33:865-883.
54. Hoare M., Levy M.S., Bracewell D.G., Doig S.D., Kong S., Titchener-Hooker N., et al. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic. Biotechnol Prog 2005, 21:1577-1592.
55. Moss R.B. Prospects for control of emerging infectious diseases withplasmid DNA vaccines. J Immune Based Ther Vaccines 2009, 7:3.
56. Shen Y., Muramatsu S.I., Ikeguchi K., Fujimoto K.I., Fan D.S., Ogawa M., et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000, 11:1509-1519.
57. Klinman D.M., Conover J., Bloom E.T., Weiss W. Immunogenicity and efficacy of a DNA vaccine in aged mice. J Gerontol A Biol Sci Med Sci 1998, 53:B281-B286.
58. Kim S.H., Kim J.Y., Choi Y., Nguyen H.H., Song M.K., Chang J. Mucosal vaccination with recombinant adenovirus encoding nucleoprotein provides potent protection against influenza virus infection. PloS One 2013, 8:e75460.
59. Li Z., Gabbard J.D., Mooney A., Gao X., Chen Z., Place R.J., et al. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J Virol 2013, 87:5985-5993.
60. Vemula S.V., Ahi Y.S., Swaim A.M., Katz J.M., Donis R., Sambhara S., et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PloS One 2013, 8:e62496.
61. Fan X., Hashem A.M., Chen Z., Li C., Doyle T., Zhang Y., et al. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes. Mucosal Immunol 2015, 8:211-220.
62. Chroboczek J., Szurgot I., Szolajska E. Virus-like particles as vaccine. Acta Biochim Pol 2013, 61:531-539.
63. Ali A., Avalos R.T., Ponimaskin E., Nayak D.P. Influenza virus assembly: effect of influenza virus glycoproteins on the membrane association of M1 protein. J Virol 2000, 74:8709-8719.
64. Zheng J., Ma J., Yang X.F., Liu H.L., Cheng H.W., Si L.S., et al. Highly efficient and economical baculovirus expression system for preparing human papillomavirus type16 virus-like particle. Acta Biochim Biophy Sin (Shanghai) 2004, 36:548-552.
65. Green K., Lew J., Jiang X., Kapikian A., Estes M. Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol 1993, 31:2185-2191.
66. Prabakaran M., Madhan S., Prabhu N., Geng G.Y., New R., Kwang J. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antivir Res 2010, 86:180-187.
67. Mallajosyula J.K., Hiatt E., Hume S., Johnson A., Jeevan T., Chikwamba R., et al. Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge. Hum Vaccin Immunother 2014, 10:586-595.
68. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
69. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res 2004, 103:173-176.
70. Zhang X., Liu M., Liu C., Du J., Shi W., Sun E., et al. Vaccination with different M2e epitope densities confers partial protection against H5N1 influenza A virus challenge in chickens. Intervirology 2011, 54:290-299.
71. Ma J.H., Yang F.R., Yu H., Zhou Y.J., Li G.X., Huang M., et al. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Virol J 2013, 10:227.
72. Zhao G., Sun S., Du L., Xiao W., Ru Z., Kou Z., et al. An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J 2010, 7:151.
73. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
74. Ebrahimi S.M., Dabaghian M., Tebianian M., Zabeh Jazi M.H. In contrast to conventional inactivated influenza vaccines, 4xM2e. HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology 2012, 430:63-72.
75. Alvarez P., Zylberman V., Ghersi G., Boado L., Palacios C., Goldbaum F., et al. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. Vaccine 2013, 31:806-812.
76. Zhao G., Du L., Xiao W., Sun S., Lin Y., Chen M., et al. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010, 28:7233-7240.
77. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8:499-508.
78. Roti M., Yang J., Berger D., Huston L., James E.A., Kwok W.W. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 2008, 180:1758-1768.
79. MacLeod M.K., David A., Jin N., Noges L., Wang J., Kappler J.W., et al. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PloS One 2013, 8:e61775.
80. Berkhoff E., De Wit E., Geelhoed-Mieras M., Boon A., Symons J., Fouchier R., et al. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol 2005, 79:11239-11246.
81. Cargnelutti D.E., Sanchez M., Alvarez P., Boado L., Mattion N., Scodeller E.A. Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant. New Microbiol 2013, 36:145-151.
82. Cummings J.F., Guerrero M.L., Moon J.E., Waterman P., Nielsen R.K., Jefferson S., et al. Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1) pdm09 virus: a Phase 1 dose-escalation study in healthy adults. Vaccine 2014, 32:2251-2259.
83. Liu G., Zhang F., Shi J., Tian G., Chen H., Yu K., et al. A subunit vaccine candidate derived from a classic H5N1 avian influenza virus in China protects fowls and BALB/c mice from lethal challenge. Vaccine 2013, 31:5398-5404.
84. Lin S.C., Liu W.C., Jan J.T., Wu S.C. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PloS One 2014, 9:e92822.
85. Du L., Zhang X., Zhou J., Chen M., He W., Zhang H.Y., et al. A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses. PloS One 2011, 6:e16555.
86. Du L., Zhao G., Sun S., Zhang X., Zhou X., Guo Y., et al. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PloS One 2013, 8:e53568.
87. Khanna M., Sharma S., Kumar B., Rajput R. Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed Res Int 2014, 2014:546274.
88. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A 2010, 107:18979-18984.
89. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010, 107:13701-13706.
90. Sui Z., Chen Q., Fang F., Zheng M., Chen Z. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 2010, 28:7690-7698.
91. Sylte M.J., Suarez D.L. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2009, 333:227-241.
92. Lu X., Liu F., Zeng H., Sheu T., Achenbach J.E., Veguilla V., et al. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus. Virology 2014, 454:169-175.
93. Doyle T.M., Hashem A.M., Li C., Van Domselaar G., Larocque L., Wang J., et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antivir Res 2013, 100:567-574.
94. Rockman S., Brown L.E., Barr I.G., Gilbertson B., Lowther S., Kachurin A., et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J Virol 2013, 87:3053-3061.
95. Liu H., Patil H.P., de Vries-Idema J., Wilschut J., Huckriede A. Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PloS One 2012, 7:e52135.
96. Prabakaran M., Velumani S., He F., Karuppannan A.K., Geng G.Y., Yin L.K., et al. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 2008, 380:412-420.
97. -adjuvanted influenza vaccine in infants and young children. Vaccine 2014, 32:6146-6156.
98. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
99. Park M.H., Chang J. Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virus. Immune Netw 2012, 12:261-268.
100. Gallorini S., Taccone M., Bonci A., Nardelli F., Casini D., Bonificio A., et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine 2014, 32:2382-2388.
101. Liu H., Patil H.P., de Vries-Idema J., Wilschut J., Huckriede A. Evaluation of mucosal and systemic immune responses elicited by GPI-0100-adjuvanted influenza vaccine delivered by different immunization strategies. PloS One 2013, 8:e69649.
102. Luo J., Zheng D., Zhang W., Fang F., Wang H., Sun Y., et al. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol J 2012, 9:286.
103. Kim M.C., Lee Y.N., Ko E.J., Lee J.S., Kwon Y.M., Hwang H.S., et al. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol Ther 2014, 22:1364-1374.
104. Kim E.H., Lee J.H., Pascua P., Song M.S., Baek Y.H., Kwon H., et al. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice. Virol J 2013, 10:104.
105. Fiers W., De Filette M., Bakkouri K.E., Schepens B., Roose K., Schotsaert M., et al. M2e-based universal influenza A vaccine. Vaccine 2009, 27:6280-6283.
106. Nayak B., Rout S.N., Kumar S., Khalil M.S., Fouda M.M., Ahmed L.E., et al. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS One 2009, 4:e6509.
107. Wu Y., Qiao C., Yang H., Chen Y., Xin X., Chen H. Immunogenicity and efficacy of a recombinant adenovirus expressing hemagglutinin from the H5N1 subtype of swine influenza virus in mice. Can J Vet Res 2014, 78:117-126.
108. Belshe R.B., Frey S.E., Graham I.L., Anderson E.L., Jackson L.A., Spearman P., et al. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. J Am Mes Assoc 2014, 312:1420-1428.
109. Madhi S.A., Cutland C.L., Kuwanda L., Weinberg A., Hugo A., Jones S., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371:918-931.
110. Kosalaraksa P., Jeanfreau R., Frenette L., Drame M., Madariaga M., Innis B.L., et al. AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial. J Infect Dis 2014, pii: jiu548.
111. Mulligan M.J., Bernstein D.I., Winokur P., Rupp R., Anderson E., Rouphael N., et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. J Am Med Assoc 2014, 312:1409-1419.
112. Berthoud T.K., Hamill M., Lillie P.J., Hwenda L., Collins K.A., Ewer K.J., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52:1-7.
113. Kreijtz J.H., Goeijenbier M., Moesker F.M., van den Dries L., Goeijenbier S., De Gruyter H.L., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 2014, 14:1196-1207.
114. Chichester J.A., Jones R.M., Green B.J., Stow M., Miao F., Moonsammy G., et al. Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthy adults. Viruses 2012, 4:3227-3244.
115. : a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 2013, 13:121-135.
116. Isai A., Durand J., Le Meur S., Hidalgo-Simon A., Kurz X. Autoimmune disorders after immunisation with influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine 2012, 30:7123-7129.
117. ): a prepandemic influenza vaccine. Expert Rev Vaccines 2012, 11:145-157.
118. Buckland B., Boulanger R., Fino M., Srivastava I., Holtz K., Khramtsov N., et al. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine 2014, 32:5496-5502.
119. Belshe R.B., Frey S.E., Graham I., Mulligan M.J., Edupuganti S., Jackson L.A., et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 2011, 203:666-673.
120. Langley J.M., Frenette L., Jeanfreau R., Halperin S.A., Kyle M., Chu L., et al. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial. Vaccine 2014, 10.1016/j.vaccine.2014.11.018.
121. Low J.G., Lee L.S., Ooi E.E., Ethirajulu K., Yeo P., Matter A., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized phase I clinical trial in healthy Asian volunteers. Vaccine 2014, 32:5041-5048.